What Creams Are Used for Precancerous Cells?

Several prescription creams treat precancerous skin cells, with fluorouracil (5-FU), imiquimod, diclofenac gel, and tirbanibulin being the most widely used for actinic keratoses, the scaly patches that sun damage leaves behind. Each cream works through a different mechanism and suits different situations, so the choice depends on how many lesions you have, where they are, and how much skin irritation you can tolerate during treatment. Some of these same creams also treat precancerous changes in other areas, including HPV-related vulvar lesions.

Why Creams Instead of Freezing or Surgery

If you have a single scaly spot on your forehead, a dermatologist can freeze it off with liquid nitrogen in seconds. But precancerous skin changes rarely show up as a lone actor. Years of sun exposure damage DNA across an entire region of skin, and the visible lesion you can see and feel is just the tip of the iceberg. The surrounding skin harbors invisible, subclinical changes that can independently progress. Dermatologists call this “field cancerization,” and it is the main reason topical creams exist as a treatment category. Freezing one spot at a time does nothing to address the broader damaged field around it.¹

Field-directed creams, by contrast, treat an entire zone of skin. You apply them to the whole sun-damaged area, not just to individual lesions. This approach reduces the risk of new actinic keratoses popping up and may lower the chance that any of them advance to squamous cell carcinoma.² Individual actinic keratoses do sometimes resolve on their own, but when you have multiple lesions in a field-cancerized zone, spontaneous regression becomes much less likely and the cumulative risk of one of them turning malignant goes up.³

Fluorouracil (5-FU)

Fluorouracil is the oldest and most studied topical treatment for precancerous skin cells. It works by blocking an enzyme that cells need to copy their DNA, which means rapidly dividing precancerous cells are hit hardest while normal skin is relatively spared.⁴ It comes in several concentrations. The classic 5% cream is applied twice daily for about four weeks on the face or scalp, with complete clearance rates in the range of roughly 43% to 77%. A 4% formulation applied once daily achieves clearance around 80%. Lower-concentration versions (0.5%) are also available, with somewhat lower clearance rates.⁵

One important real-world finding: the skin reactions that 5-FU causes, the redness, crusting, and soreness that make people want to quit, are actually linked to how well it works. A post-hoc analysis of two randomized trials found that more severe local skin reactions during 5-FU 4% treatment were associated with higher clearance rates. Severe reactions did not compromise how effective the treatment was. That said, the reactions can still be deeply unpleasant, and some patients stop treatment early because of them.⁶ Knowing that the redness is a sign the cream is working can help you push through the treatment course rather than abandoning it halfway.

Beyond clearing visible lesions, there is evidence that 5-FU reduces the downstream risk of actual skin cancer. In a Veterans Affairs randomized trial, the group treated with 5-FU had significantly fewer treatment encounters for squamous cell carcinoma a year later compared to the control group.⁷

Imiquimod

Imiquimod takes a completely different approach from fluorouracil. Rather than directly killing precancerous cells, it activates your own immune system to do the job. The cream triggers a receptor on immune cells called TLR7, which sets off a cascade of inflammation and immune signaling. Dendritic cells mature and become better at presenting abnormal cell markers to the rest of the immune system. T cells flood the treated area.⁸ The result is that your body learns to recognize and destroy the precancerous cells, with the inflammatory response serving as both the mechanism and, unfortunately, the main side effect.

The 5% cream is FDA-approved for actinic keratoses on the face and balding scalp, applied three times a week in two four-week cycles separated by a few weeks off. Complete clearance rates run in the range of roughly 54% to 55%. Lower concentrations (3.75% and 2.5%) exist for treating larger areas, with somewhat lower clearance rates but the advantage of being applicable to bigger skin zones.⁵ Imiquimod is also approved for superficial basal cell carcinoma and genital warts, making it one of the more versatile topical treatments in dermatology.

Diclofenac Gel

Diclofenac 3% in hyaluronic acid gel is the gentlest option for actinic keratoses, but it is also the least potent. The cream is a nonsteroidal anti-inflammatory drug (NSAID), the same class as ibuprofen, formulated for the skin. Its effects on precancerous cells appear to involve reducing inflammation, inhibiting the growth of new blood vessels that feed abnormal cells, and slowing cell proliferation.⁹

The tradeoff is clear: you apply it twice daily for 60 to 90 days, which is a much longer treatment course than any other option, and complete clearance sits around 41%.⁵ A Cochrane review confirmed that diclofenac gel significantly outperforms placebo but falls well behind 5-FU and imiquimod in head-to-head network comparisons.¹⁰ Its main appeal is tolerability. If you cannot handle the aggressive skin reactions of 5-FU or imiquimod, diclofenac is a lower-intensity alternative, though you should expect a longer commitment and a lower chance of total clearance.

Tirbanibulin

Tirbanibulin 1% ointment is the newest entry, approved in 2020. Its mechanism is distinct from all the older creams. It targets the structural scaffolding inside cells, specifically the microtubules that cells need to divide. By blocking tubulin from assembling properly, tirbanibulin causes cell-cycle arrest in rapidly proliferating precancerous cells. It also interferes with a signaling pathway involving Src, a protein that can drive progression from precancerous changes to squamous cell carcinoma.¹¹ The cellular effects appear to be reversible in normal cells, which may explain why the cream is relatively well tolerated.¹²

The biggest practical advantage is the treatment schedule: once daily for just five days. That is dramatically shorter than the weeks-long courses required by every other cream. Complete clearance rates sit around 49%, which places it in the middle of the pack.⁵ A European network meta-analysis comparing all major topical treatments found tirbanibulin’s odds of complete clearance were roughly comparable to cryosurgery and photodynamic therapy with MAL, though behind 5-FU 5% and 5-FU 4%.¹³

How the Creams Compare

Choosing between these treatments involves balancing efficacy, treatment duration, side effects, and which body site is being treated. A large Cochrane review found that all four major field-directed creams (5-FU, imiquimod, diclofenac, and the now-discontinued ingenol mebutate) significantly outperformed placebo for complete clearance. Among them, 5-FU and imiquimod consistently showed the strongest results.¹⁰

The European network meta-analysis put numbers on these comparisons. Against placebo, 5-FU 5% and 4% had the highest odds of complete clearance, followed by photodynamic therapy with ALA, imiquimod 5%, cryosurgery, and then tirbanibulin in roughly that order. Diclofenac trailed significantly behind the rest.¹³ But raw clearance rates are not the whole story. A cream that clears 80% of lesions but makes you miserable for a month may not be the right choice if a five-day course of something else can clear half your lesions with minimal discomfort, especially if you plan to repeat the treatment cycle.

Here is a practical summary of the main options:

5-FU 4% or 5%: Highest clearance rates. Applied daily or twice daily for about four weeks. Expect significant redness, crusting, and discomfort.
Imiquimod 5%: Strong clearance with an immune-based approach. Applied three times weekly over two four-week cycles with rest periods between. Skin reactions are common and can be intense.
Tirbanibulin 1%: Moderate clearance. Applied once daily for five days. Generally the best-tolerated option with the shortest course.
Diclofenac 3% gel: Lowest clearance rates. Applied twice daily for 60 to 90 days. Mild side effects but a very long treatment commitment.

The Calcipotriol Combination

One of the more interesting developments in recent years is the combination of 5-FU with calcipotriol, a synthetic form of vitamin D normally used for psoriasis. The idea is that calcipotriol primes the skin’s immune system so that when 5-FU kills precancerous cells, the immune system gets a stronger signal to recognize and attack any remaining abnormal tissue.¹⁴

A randomized trial tested this combination against 5-FU alone (mixed with plain Vaseline), using a short four-day treatment. The results were striking. On the face, the combination reduced actinic keratoses by about 88% compared to roughly 26% with 5-FU alone. On the scalp, the gap was even wider: about 76% versus 6%. Similar advantages held on the arms.¹⁵ A four-day course that achieves those numbers would be a major advance in patient convenience and compliance, though the combination is not yet available as a single commercial product. Some dermatologists prescribe the two creams to be mixed and applied together off-label.

Photosensitizing Creams for Photodynamic Therapy

Photodynamic therapy (PDT) is technically an in-office procedure, but it starts with a cream. A photosensitizing agent, either aminolevulinic acid (ALA) or methyl aminolevulinate (MAL), is applied to the treatment area and left on for several hours. During that time, precancerous cells absorb the cream and convert it into a light-sensitive compound that accumulates preferentially in abnormal tissue.¹⁶ Then the area is exposed to a specific wavelength of light, which activates the compound and destroys the cells from the inside.

PDT achieves some of the highest clearance rates for actinic keratoses on the face and scalp, ranging from roughly 69% to 93% depending on the protocol.⁵ A daylight variant has emerged in recent years where, instead of a special lamp in the clinic, you simply go outside after cream application and let natural light do the activation. Daylight PDT is less painful and achieves clearance rates in the range of 70% to 89%. The cream itself is not something you take home and use on your own schedule the way you would with 5-FU or imiquimod. You get the cream as part of the office visit.

Creams for Precancerous Cells Beyond the Skin Surface

Actinic keratoses get the most attention, but precancerous cells also develop in other locations where topical creams play a role. The most common example is vulvar high-grade squamous intraepithelial lesions (vHSIL), precancerous changes on the vulva usually driven by HPV infection. In a landmark randomized trial, 5% imiquimod cream reduced vulvar lesion size by more than 25% in 81% of treated patients, compared to none in the placebo group. HPV cleared from the lesion in 58% of the imiquimod group versus 8% of those receiving placebo.¹⁷

A systematic review comparing imiquimod to surgery and laser ablation for vulvar precancers found that complete response rates for imiquimod ranged from 25% to 81% across studies, while surgical excision ranged from 55% to 100% and CO₂ laser ablation from 44% to 85%. But recurrence rates were similarly variable across all approaches: 0% to 83% for imiquimod, 8% to 81% for surgical excision, and 27% to 56% for laser.¹⁸ The wide ranges reflect differences in study design, follow-up duration, and patient populations more than they reflect genuine randomness in outcomes. The takeaway is that imiquimod is a legitimate nonsurgical alternative for vulvar precancers, especially when surgery would be cosmetically or functionally damaging, though it does not match the ceiling clearance rates of excision.

Side effects in the vulvar area tend to mirror what happens on the skin: redness, erosion, pain, and itching at the application site, with dose reductions needed more often in the imiquimod group than in placebo groups.¹⁹ The treatment is typically applied two to three times weekly for 12 to 24 weeks, considerably longer than the skin-based protocols.

Precancerous Changes on the Lips

Actinic cheilitis is the lip equivalent of an actinic keratosis, a sun-damaged, persistently dry or scaly patch on the lower lip that carries real risk of progressing to squamous cell carcinoma. Creams used for actinic keratoses elsewhere on the body are also used here, but the lip is a challenging location. The skin is thinner, the area is constantly in motion from talking and eating, and topical treatments can be particularly uncomfortable.

A systematic review and meta-analysis of interventions for actinic cheilitis found that diclofenac achieved a pooled complete clearance rate of about 53%, while laser treatments reached the highest clearance rates. Imiquimod stood out for having the lowest recurrence rate among treatments evaluated.²⁰ The evidence base for lip precancers is smaller than for actinic keratoses elsewhere, so treatment decisions here lean more heavily on clinical judgment and patient tolerance.

The Cost Picture

Managing actinic keratoses is expensive on a population level. An analysis of nearly half a million continuously enrolled insurance members with actinic keratosis claims found that total costs reached about $112 million over two years, and there was enormous variation in per-patient costs, with the highest-cost patients spending up to 15 times more than the lowest-cost patients before adjustment.²¹ This variation partly reflects the difference between patients with a few isolated spots who get occasional cryotherapy and those with widespread field cancerization requiring repeated courses of topical treatment, office-based procedures, or both.

Generic fluorouracil 5% is one of the least expensive prescription options, with tubes often costing under $50 with insurance. Imiquimod has come down in price since going generic but still tends to be more expensive. Tirbanibulin, being the newest and still brand-name only, carries a significantly higher price tag. Diclofenac gel sits somewhere in the middle. Photodynamic therapy is the most expensive per session because it involves an office visit, the photosensitizing cream, and the light source. These costs influence real-world prescribing: many dermatologists start with generic 5-FU because of its combination of strong efficacy and low cost, reserving the newer or more expensive options for patients who cannot tolerate it or who have not responded.

Formulation Challenges and Emerging Research

One barrier to improving topical treatments is getting enough active drug through the outer layer of skin. Imiquimod, for instance, dissolves very poorly in water, which limits how much of the drug actually reaches the target cells. Research into new formulation strategies, such as using micelle-based delivery systems, has shown that alternative formulations can increase the amount of imiquimod that penetrates skin by 25 to 42 times compared to commercial cream formulations.²² These formulations are still experimental, but they point toward a future where existing drugs could work better simply because more of the medication reaches the cells that need it.

The calcipotriol-plus-5-FU combination is another area of active development. A four-day treatment that dramatically outperforms a standard four-week 5-FU course would reshape how dermatologists approach field cancerization, if the results hold up in larger trials and real-world practice. Researchers are also exploring whether these immune-priming strategies could generate a lasting “memory” effect, where the immune system stays on alert against precancerous cells long after the cream is gone, potentially reducing both recurrence and progression to squamous cell carcinoma over years rather than months.

1
SKIN The Journal of Cutaneous Medicine. The Role of Field Cancerization in Selecting Therapies for Actinic Keratosis: An Expert Consensus Panel
2
PubMed. Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review
3
PubMed Central. The State of the Art in the Treatment of Actinic Keratosis and Field Cancerization: A Narrative Review
4
JAMA Dermatology. Fluorouracil: Mechanism of Action in Human Skin and Actinic Keratoses: I. Effect on DNA Synthesis in Vivo
5
PubMed Central. A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
6
PubMed Central. Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials
7
PubMed. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis
8
PubMed. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial
9
PubMed. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis
10
Cochrane Database of Systematic Reviews. Interventions for actinic keratoses
11
PubMed. Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis
12
PubMed Central. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action
13
PubMed Central. Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
14
PubMed Central. Calcipotriol and 5-Fluorouracil Combination Therapy for the Treatment of Actinic Keratosis in the Clinic: A Review Article
15
The Journal of Clinical Investigation. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy
16
PubMed. Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy
17
PubMed. Treatment of vulvar intraepithelial neoplasia with topical imiquimod
18
PubMed Central. Evaluating the effectiveness of various treatment modalities in vulvar high-grade squamous intraepithelial lesions (vHSIL): a systematic review
19
PubMed Central. Medical interventions for high-grade vulval intraepithelial neoplasia
20
PubMed Central. Actinic Cheilitis: A Systematic Review and Meta-Analysis of Interventions, Treatment Outcomes, and Adverse Events
21
JAMA Dermatology. Variation in the Cost of Managing Actinic Keratosis
22
PubMed Central. Improvement of Imiquimod Solubilization and Skin Retention via TPGS Micelles: Exploiting the Co-Solubilizing Effect of Oleic Acid